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Abstract
Tylophorine and related natural compounds exhibit potent antitumor activities. We previously
showed that PBT-1, a synthetic C9-substituted phenanthrene-based tylophorine (PBT) derivative,
significantly inhibits growth of various cancer cells. In this study, we further explored the
mechanisms and potential of PBT-1 as an anticancer agent. PBT-1 dose-dependently suppressed
colony formation, induced cell cycle G2/M arrest and apoptosis. DNA microarray and pathway
analysis showed that PBT-1 activated the apoptosis pathway and mitogen-activated protein kinase
signaling. In contrast, PBT-1 suppressed the nuclear factor kappaB (NF-κB) pathway and focal
adhesion. We further confirmed that PBT-1 suppressed Akt activation accelerated RelA degradation
via IκB kinase-α, and downregulated NF-κB target gene expression. The reciprocal recruitment of
RelA and RelB on COX-2 promoter region led to downregulation of transcriptional activity. We
conclude that PBT-1 induces cell cycle G2/M arrest and apoptosis by inactivating Akt and by
inhibiting the NF-κB signaling pathway. PBT-1 may be a good drug candidate for anticancer
chemotherapy.
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Introduction
Natural products have long been major sources of anticancer and other drugs. Several plants
of the Tylophora genus have been used medicinally as anti-inflammatory, antiarthritis, and
antiamebic agents in East Asia.1 The phenanthroindolizine alkaloid tylophorine and its analogs
are found primarily in plants of the Asclepiadaceae family, including members of the
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Tylophora genus.2 Although tylocrebrine, a natural product related to tylophorine, failed in
anticancer clinical trials in 1966 because of toxicity to the central nervous system (CNS),
certain cytotoxic analogs were reevaluated for antitumor potential by the National Cancer
Institute (NCI) using a 60-tumor cell line panel. As we reported previously, a series of novel
polar water-soluble synthetic phenanthrene-based tylophorine derivatives (PBTsa) exhibit
potent cytotoxic activity against the A549 human lung cancer cell line.3 These compounds
may have little or no CNS toxicity because their increased polarity should prevent them from
penetrating the blood–brain barrier. Compound PBT-1 showed modest in vivo antitumor
activity against human A549 xenografts in nude mice and potent in vitro cytotoxic activity.4
Tylophorine analogs exhibit potent growth-inhibitory activity against a broad range of human
cancer cells,5–10 and this antitumor activity results from the irreversible inhibition of protein
synthesis at the elongation stage of the translation cycle.11–13 Several key metabolic enzymes,
including thymidylate synthase9 and dihydrofolate reductase have been reported as biological
targets of tylophorine alkaloids.8 Tylophorine derivatives also inhibit activator protein-1–
mediated, CRE-mediated, and nuclear factor kappaB (NF-κB)-mediated transcription.14, 15
These discoveries illustrate the potential of tylophorine derivatives as a new class of antitumor
drugs. However, the comprehensive evaluation of the antitumor activity of tylophorines has
not been reported, and the mechanism responsible for the inhibitory effects on cancer cell
growth is largely unknown.
We used cDNA microarray analysis to investigate the antitumor activity of tylophorine analogs
against human lung cancer cells and analyzed the effect of PBT-1 on gene expression. Based
on the microarray data, we explored the possible signaling pathways that may inhibit cell
growth and induce apoptosis. The effects of tylophorine analogs on key signaling pathways
were also investigated.
Results
Effect of PBT Series Compounds on Cancer Cell Cytotoxicity
Our previous data showed that novel 9-substituted 2,3-methylenedioxy-6-methoxy-PBTs
exhibit potent cytotoxic activity against certain human cancer cell lines, including a multidrug-
resistant variant.4 However, the biological functions of these PBTs have not been explored.
To identify the pharmacophores relating to the high potency of the new PBT series, 10
compounds were examined. Their structures are shown in Fig. 1A. The inhibitory effect of the
drugs was calculated as the percentage of viable drug-treated cells compared with the
percentage of viable cells in the untreated control. The median inhibitory concentration
(IC50) value was defined as the concentration of drug that inhibited cell growth by 50%. The
CL1-0 lung cancer cell line was exposed to increasing concentrations of compounds for 48 h.
PBT-1, PBT-2, PBT-9, and PBT-10 exhibited dose-dependent growth inhibition, with IC50
values of 0.81, 0.44, 0.37, and 0.46 µg/mL, respectively, at 48 h (Fig. 1B). The IC50 values of
the six remaining compounds were > 2 µg/mL; PBT-3, PBT-7, and PBT-8 exhibited greater
cytotoxic activity than PBT-4, PBT-5, and PBT-6. These results indicate that the structural
features contributing to the greatest cytotoxic effects on lung cancer cells are a pendant
pyridine/pyridinium ring with a hydroxymethyl or hydroxyethyl substituent, as found in
PBT-1, PBT-2, PBT-9, and PBT-10.
PBT-1 Can Suppress Lung Cancer Cell Growth
To explore the antitumor potential of PBTs, CL1-0, CL1-5, H460, PC-9 and A549 lung cancer
cells as well as BEAS2B, immortalized normal bronchial epithelial cells, were treated with the
aAbbreviations: PBTs, phenanthrene-based tylophorine derivatives.
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highly potent compound PBT-1, and cell viability was determined by the MTS assay. The
resulting IC50 values for PBT-1 were around 0.2 ~ 0.4 µg/mL against these lung cancer cells
but no significant inhibition on BEAS2B cells (Fig. 2A). With increasing concentration of the
drug, CL1-0 cells treated with PBT-1 showed cell shrinkage and rounding, followed by broken
membranes (Fig. 2B). The inhibitory effect of PBT-1 on the colony formation of CL1-0 cells
was calculated as the percentage of visible colonies of the drug-treated groups compared with
the percentage in the untreated control groups. Treatment with PBT-1 also suppressed colony
formation in a dose-dependent manner. The growth of CL1-0 cells was suppressed fully when
the concentration of PBT-1 was > 0.25 µg/mL.
PBT-1 Induces Cell Cycle Arrest in the G2/M Phase and Activates Apoptotic Proteins
To understand the mechanism of PBT-1's effect on cell growth, we used DNA flow cytometry
to investigate changes in the cell cycle in CL1-0 cells treated with PBT-1. Treatment with
PBT-1 time-dependently decreased the proportion of cells in the G0/G1-phase and increased
the proportion of cells in the G2/M-phase up to 12 h (Fig. 3A). Interestingly, a sub-G1 peak
and an S-phase peak appeared after 16 h of PBT-1 treatment. To confirm this cell cycle analysis,
we measured the effects of PBT-1 on regulatory proteins of cell cycle progression. Western
blot analysis indicated that treatment with PBT-1 caused cyclin B1 and cyclin D1 protein
accumulation in a dose-dependent manner but had no effect on cyclin A, cyclin E, p21, or p27
protein levels (Fig. 3B). In addition, Annexin V and Western blot analyses indicated that
treatment with PBT-1 induced apoptosis of lung cancer cells (Fig. 3C and 3D).
Gene Expression Profiles of Lung Cancer Cells after PBT-1 Treatment
To elucidate the molecular mechanism of PBT-1's induction of cell apoptosis, we used a cDNA
microarray with Gene Spring software to analyze the changes in gene expression after PBT-1
treatment. In total, 1437 putative genes showed a statistically significant twofold difference in
expression in CL1-0 lung cancer cells after 24 h of PBT-1 treatment (0.5 µg/mL) compared
with untreated control cells. Of these 1437 genes, 883 were upregulated and 554 were
downregulated. The genes were upregulated or downregulated to a similar extent. The
upregulated genes are those involved in signal pathways such as mitogen-activated protein
kinase (MAPK); the apoptotic pathway was activated markedly after treatment with PBT-1.
In contrast, focal adhesion and metabolic pathway genes were downregulated significantly by
treatment with PBT-1. Some of these PBT-1–induced genes are listed and categorized by their
putative functions in Table 1. Protein kinase A, CASP8 and FADD-like apoptosis regulator,
Tumor necrosis factor receptor 10b, MAPK kinase kinase 14, and NF-κB inhibitor-α were
upregulated significantly (twofold) by PBT-1 treatment. The microarray data was also
confirmed by real-time RT-PCR.
PBT-1 Can Activate Cell Apoptosis Pathways
To predict the putative signaling pathway involved in PBT-1 stimulation, we used the KEGG
and BIOCARTA pathway databases to analyze the differentially expressed profiles of PBT-1–
induced genes to fit the transduction-signaling map. Two major pathways were upregulated
by PBT-1: the cell cycle regulatory pathway and the apoptotic pathway. Cell cycle analysis
showed that PBT-1 increased the expression of cdc25a (2.9-fold) and cyclin D1 (2.1-fold), and
decreased the expression of cyclin A (0.33-fold) (Fig. 4A). The results for the apoptosis
pathway showed that PDK1 and Akt were downregulated (0.26- and 0.48-fold), and IκB were
upregulated (2.2-fold). These data suggest that PBT-1 suppresses the NF-κB signaling pathway
by suppressing Akt–IKK activation (Fig. 4B).
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PBT-1 Inhibits Akt Phosphorylation and NF-κB Activation
To confirm whether PBT-1 can suppress the activation of both Akt and NF-κB, we used
Western blot analysis and an NF-κB reporter assay to examine the changes in Akt and NF-κB
activity after PBT-1 treatment. Western blot analysis confirmed that Akt phosphorylation
decreased and IκB protein increased in a dose-dependent manner when CL1-0 cells were
exposed to increasing PBT-1 concentration (Fig. 5A). The reporter assay showed that NF-κB
transcriptional activity was induced by stimulation with TNF-α and that PBT-1 dose-
dependently suppressed TNF-α–induced NF-κB transcriptional activity in CL1-0 cells (Fig.
5B). Western blot analysis showed that phosphor-Akt increased after TNF-α treatment but that
the TNF-α–induced activation of Akt was inhibited by PBT-1 in both CL1-0 and A549 cells
(Fig. 5C). In addition, RelA and IκB protein decreased when the cells were cotreated with TN-
Fα and PBT-1. The expression level of COX-2, a gene known to be downstream of NF-κB,
was high in cells treated with TNF-α, but its expression decreased in cells exposed to PBT-1.
Interestingly, the activity of IKKα, but not IKKβ, increased after treatment with PBT-1 (Fig.
5D). The chromatin IP assay showed a decreased binding affinity of RelA and NF-κB1 (p50)
to the NF-κB response element on the COX-2 promoter in A540 cells. In contrast, the binding
activity of ReIB was higher after exposure to PBT-1 co-treated with TNF-α than after exposure
to TNF-α alone, but the binding activity of ReIB decreased when exposed to PBT-1 at a
concentration > 0.25 µg/mL (Fig. 5E).
Discussion
In this study, we demonstrated that the PBT analog PBT-1 has potent cytotoxicity against
various lung cancer cells and can induce cell cycle G2/M arrest and apoptosis. The microarray
data showed that PBT-1 increases the expression of genes belonging to certain signaling
pathways, such MAPK and apoptosis, and dramatically suppresses the expression of genes for
metabolic enzyme. These data indicate that PBT-1 treatment can regulate these signaling
pathways. We showed further that the key signaling pathways affected in lung cancer cell
survival involve inactivation of Akt and NF-κB. Our data suggest that PBT-1 affects cell growth
by inhibiting the NF-κB signaling pathway. This suggests that PBT-1 is a good candidate for
anticancer therapy.
Tylophorine compounds comprise a new class of anticancer agents because of their novel
chemical structure combined with the unique spectrum of activity compared with current
antitumor drugs, based on NCI tumor cell panel studies. Because a related compound,
tylocrebrine, failed in clinical trials because of CNS toxicity, investigators have since tried to
develop derivatives that are not toxic to the CNS. We designed and synthesized a series of
novel 9-substituted 2,3-methylenedioxy-6-methoxy-PBTs, and one analog (PBT-1) showed in
vivo activity in a murine model without overt toxicity to the animals.3, 4 The biological
function and molecular mechanism responsible for the effect of PBT-1 on cell cytotoxicity
merit investigation. Interestingly, CL1-0 and CL1-5 cells, which were both isolated from the
same original clinical sample, exhibited the same sensitivity (IC50) to PBT-1, even though they
have different intensities of invasive ability. This suggests that the key mechanism responsible
for PBT-1’s ability to suppress cell growth is involved in tumorigenesis but not in the invasion
machinery.
To elucidate the mechanism of action of PBT-1, we examined its effect on cell cycle
progression. We found that PBT-1 induced G2/M arrest, which was accompanied by
accumulation of cyclin B1 (Fig. 2) and activation of the MAPK signaling pathway, as predicted
by our microarray data (Table 1). Interestingly, paclitaxel also induces cyclin B1 accumulation,
16 cell cycle G2/M arrest, and apoptosis through an MAPK-dependent pathway.17 Thus,
PBT-1 and paclitaxel may activate the same death-signaling pathway to induce cell apoptosis.
Gao et al. found a dose-dependent S-phase accumulation at 24 h in human nasopharyngeal
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carcinoma KB cells treated with another tylophorine analog class (DCBs) developed by their
laboratory.15 They also demonstrated that, in human pancreatic duct carcinoma cells, the
percentage of G2/M-phase cells increased gradually with time of exposure to a tylophorine
analog, whereas the percentage of S-phase cells increased initially and then decreased with
exposure time.18 We found that PBT-1 treatment increased the percentage of G2/M-phase
cells at 12 h, but this was followed by a decreased percentage of G2/M-phase cells and a
corresponding increased percentage of S-phase cells after 16 h. These contrasting effects may
relate to the variant behavior of cell types and differences in the particular tylophorine analogs.
However, our microarray data also suggest that these compounds decrease cell growth by
interrupting the regulatory proteins in cell cycle progression (Fig. 4B).
NF-κB is a key transcription factor for the inflammatory response,19 tumor progression,20
and drug resistance.21, 22 Suppression of NF-κB activity leads to induction of an apoptotic
response.23 Thus, NF-κB is an important therapeutic target in cancer treatment.24 Using a
cDNA microarray technique, we found that treatment of cells with PBT-1 led to
downregulation of Akt and upregulation of IκB. These results suggest two possible
mechanisms: 1) that there is a link between Akt inactivation and IκB accumulation and 2) that
NF-κB activity may be suppressed by PBT-1 treatment because of IκB accumulation. IKK
regulates IκB degradation by phosphorylation, and IKK activity is regulated by Akt.25, 26
Thus, suppression of Akt by PBT-1 treatment could explain why IκB can escape protein
degradation and accumulate in the cytoplasm.
The abundant dephosphorylated IκB can bind NF-κB to block its translocation from the
cytoplasm to nucleus so that downstream genes of NF-κB, such as COX-2, cannot be expressed.
Contrary to expectation, we found that PBT-1 can upregulate but cannot suppress the
expression of IKKα and its phosphorylation. Lawrence et al. demonstrated that IKKα can
suppress NF-κ activity by accelerating both the turnover of NF-κB subunits RelA and c-Rel,
and their removal from proinflammatory gene promoters, resulting in the resolution of
inflammation in macrophages.27 These results are consistent with our finding that RelA
degradation correlated with the increasing expression of IKKα upon treatment with PBT-1.
Interestingly, our data showed that RelB, a downstream gene of IKKα, was also activated by
PBT-1treatment (Fig. 5). Other studies demonstrated that RelB plays a role in endotoxin
(lipopolysaccharide)-induced tolerance and anti-inflammatory effects through the reciprocal
recruitment of RelA and RelB to NF-κB target gene promoters, resulting in the downregulation
of NF-κB target genes.28, 29 Taken together, these results indicate that PBT-1 may activate
an alternative NF-κB pathway to inhibit the canonical NF-κB pathway induced by
proinflammatory cytokines by activating IKKα.30 This novel finding provides a unique
perspective on the traditional anti-inflammatory and antiarthritis uses of Tylophora alkaloids;
namely, that these compounds can remit the symptoms of asthma and inflammation by
activating the IKKα–RelB pathway to tolerate the immune response induced by environmental
stimulation, as well as autoimmune diseases. However, this hypothesis needs to be further
studied.
Akt (protein kinase B) has been identified as a downstream target of growth factor receptor
activation, such as by insulin-like growth factor, epidermal growth factor, basic fibroblast
growth factor, insulin, interleukin-6, and macrophage colony stimulating factor.31–33 Akt
controls vital cellular functions such as cell survival, cell cycle progression, and glucose
metabolism. The Akt gene is overexpressed and is constitutively active in many human cancers.
34–39 Bad, a proapoptotic member of the Bcl-2 family, is a substrate of Akt, which can
phosphorylate Bad significantly at Ser136 and then inhibit its proapoptotic functions.40, 41
Inactivation of Akt is considered an attractive approach for chemotherapy. Recent studies have
shown that inhibition of Akt alone or in combination with other cancer chemotherapeutics can
reduce the threshold of apoptosis and kill cancer cells.42, 43 We found that PBT-1 can suppress
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inducible activation of Akt in lung cancer cells. Intriguingly, the inactivation of Akt by PBT-1
treatment correlated with the downregulation of COX-2 but not with IKK activity. This
suggests that PBT-1, a novel Akt inhibitor, can regulate the Akt-dependent regulation of NF-
κB through other mediators, such as mTOR, which regulates IKK activity.44 The mechanism
for this action remains unclear. Taken together, our data show that PBT-1 may be a highly
promising, anticancer drug that suppresses cancer cell growth by inhibiting Akt and NF-κB
activity. However, the detailed molecular mechanism of this PBT-1–related suppression of Akt
activation and NF-κB requires further investigation.
In conclusion, we have shown that PBT-1 can induce cell cycle G2/M arrest and apoptosis by
interrupting the regulatory proteins in cell cycle progression and by inhibiting the NF-κB
signaling pathway by inactivating Akt. This new class of tylophorine compounds has a unique
mode of action that differs from that of other known antitumor compounds. PBT-1 or a future
analog will be a good candidate for a new agent for anticancer therapy.
Experimental Section
Cell Lines
The human lung adenocarcinoma cell lines CL1-0 and CL1-5 were established in our
laboratory,45, 46 and with A549 cells (American Type Culture Collection CCL-185) were
grown in normal RPMI 1640 culture medium (GIBCO-Life Technologies, Inc., Gaithersburg,
MD) or Dulbecco’s modified Eagle’s medium (GIBCO-Life Technologies), supplemented
with 1.5 g/L of NaHCO3, 4.5 g/L glucose, and 10% fetal bovine serum (FBS; GIBCO-Life
Technologies). Tumor necrosis factor-α(TNF-α) was purchased from Peprotech (Rocky Hill,
NJ). H460, PC-9 and BEAS2B cells were gifted from Dr. Ker-Chau Li, Dr. Chih-Hsin Yang
and Dr. Reen Wu, respectively.
Compounds
Ten tested phenanthrene-based derivatives (PBT-1–PBT-10) were synthesized by Dr. KH Lee's
laboratory.3, 4
Cell Proliferation Assay
Cell proliferation was measured by using a CellTiter 96 Aqueous Non-radioactive Cell
Proliferation Assay kit (Promega, Madison, WI). Cells were transferred in four replicates to a
96-well plate at a concentration of 2 × 103 cells/well in 100 µL of complete RPMI 1640 with
or without the drugs. The cells were incubated at 37 °C in 5% CO2 for 48 h, the viability of
the cells was analyzed after the addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent to the cultured
cells, and the cells were lysed according to the manufacturer’s instructions. Absorbance was
determined using Emax microplate reader (Molecular Devices, Union City, CA) at a
wavelength of 490 nm.
Colony Formation Assay
Cells (5 × 102/well) were plated in six-well plates. After 24 h, cells were exposed to serial
dilutions of the drugs for the times indicated. Five hundred or 1,000 viable cells were plated
in triplicate in six-well plates, grown for 10 to 14 days, fixed, and stained with 0.5% methylene
blue in 50% ethanol for 1 h. The plates were washed and dried, and the colonies were counted
to obtain a cloning efficiency for each drug concentration.
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A total of 2 × 105 CL1-0 cells/dish were seeded onto each 60 mm dish and incubated for 24
hours. Various concentrations of PBT-1 were added to the culture media and the cells were
incubated for an additional 2, 6, 12, 16, and 24 h. Cells were harvested and fixed in cold 70%
ethanol at 4 °C for 16 h and incubated with 20 µg/mL of RNase A at 37 °C for 30 min and then
with 50 µg/mL of propidium iodide (PI) at 4 °C for 30 min. Samples were analyzed immediately
by flow cytometry (BD Biosciences, San Jose, CA). The cell cycle phase distribution was
determined using CellQuest software (BD Biosciences).
Western Blot Analysis
Equal amounts (50 µg) of cell lysate were separated by 10% SDS–PAGE, and transferred to
a polyvinylidene membrane (Millipore, Billerica, MA). The membrane was probed with
antibodies directed against cyclin A (Santa Cruz Biotechnology, Santa Cruz, CA), cyclin B1,
cyclin D1, cyclin E, p21, p27, RelA, p-Akt, Akt, IκB kinase α (IKKα), p-IKKα/β, and α-actin
(all from Sigma, St Louis, MO). Antibodies were diluted in TBS (pH 7.5) containing 0.05%
(v/v) Tween 20 and 5% (w/v) dried milk. Blots were incubated with the appropriate horseradish
peroxidase-conjugated secondary antibodies (Amersham Biosciences, Uppsala, Sweden).
Bound antibodies were visualized by electrochemical luminescence staining with
autoradiographic detection using Kodak X-Omat Blue film (PerkinElmer Life Science, Boston,
MA).
Apoptosis Assay
Control or treated cells were resuspended in Annexin-binding buffer, stained with Alexa Fluor
488 Annexin V or PI,42 and incubated at room temperature for 15 min. The cells stained only
with Annexin V were used as the positive control to set the apoptotic window, and the cells
stained only with PI were used as the positive control to set the necrotic window. Double-
stained, formaldehyde-treated cells were mainly necrotic. The acquired data were analyzed
using CellQuest software (BD Biosciences).
DNA Microarray Analysis
The detailed protocol for the human DNA microarray analysis has been reported in our previous
studies.47, 48 Total RNA was extracted from the CL1-0 cells incubated with or without the
drugs using RNAzol B solution (Life Tech, Gaithersburg, MD), and the mRNA was extracted
using an mRNA isolation kit (Qiagen, Hilden, Germany), according to the manufacturer’s
protocol. Five micrograms of mRNA from each sample was used in each array. The microarray
images were scanned, digitized, and analyzed using a flatbed scanner (PowerLook 3000;
UMAX, Taipei, Taiwan) and GenePix 3.0 software (Axon Instruments, Union City, CA). When
designing the microarray experiments, we adhered to the guidelines of the Microarray Gene
Expression Data Society (www.mged.org/Workgroups/MIAME/miame_checklist.html).
Identification of Pathways Using the KEGG and BioCarta Databases
Gene identification was performed to determine which biochemical pathways were altered
during treatment with PBT-1. Having identified genes on the basis of the cDNA microarray
data, we were also interested in determining whether any of these genes were part of the same
pathway. Accordingly, we searched the Kyoto Encyclopedia of Genes and Genomes (KEGG)
(http://www.genome.ad.jp/kegg/pathway.html) and the BioCarta
(http://www.biocarta.com/genes/allpathways.asp) biochemical pathway database using the
genes selected from cDNA microarray analysis described previously.49
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Real-Time quantitative RT-polymerase chain reaction
To validate the microarray data, real-time quantitative RT-PCR was performed according to
our previous described method.48 Primers were performed as listed on Table 1. All reactions
were carried in 20 µl volumes containing 10 µl of iTaqTM Fast SYBR Green Supermix with
ROX (Bio-Rad, Hercules, CA). GAPDH was performed as internal control.
Transient Transfection and Luciferase Activity
Adherent cells (1 × 105) cells in six-well plates were transiently transfected with 0.2 µg of a
pNf-κB-Luc vector (Stratagene, La Jolla, CA) and 1 µg of pSV-β-galactosidase vector
dissolved in 10 µL lipofectamine (Invitrogen, Carlsbad, CA) as the internal control. The
plasmids were transfected according to the manufacturer’s instructions. After 20 h, the medium
was changed to serum-free medium, the cells were pretreated with increasing concentrations
of PBT-1 as indicated for 1 h, and the cells were stimulated with various concentrations of
TNF-α as indicated for 4 h. Cell extracts were harvested using 250 µL of lysis buffer (Tropix,
Inc., Bedford, MA) per well. To measure the luciferase and β-galactosidase activities, cell
extracts (20 µL each) were assayed separately using the Luciferase Assay Kit and Galacto-
Light Plus™ system (Tropix, Inc.), respectively. Luciferase activity was measured and
analyzed using an FB12 luminometer (Zylux Corporation, Oak Ridge, TN).
Chromatin Immunoprecipitation (ChIP) Assay
The chromatin immunoprecipitation assay has been described previously.50 Briefly, A549
cells were cross-linked with 1% formaldehyde and the reaction was stopped with 0.125 M
glycine. The cells were solved in 250 µL of cell lysis buffer. The pelleted nuclei were suspended
in 150 µL of nuclei lysis buffer and diluted with immunoprecipitation (IP) dilution buffer. The
samples were sonicated at 12 W for 45 s. The DNA–protein supernatant was reacted with anti-
RelA (Santa Cruz), anti-p50, and anti-RelB antibodies at 4 °C overnight. The
immunoprecipitated complexes were collected with protein A/G Sepharose beads (Sigma) and
then washed sequentially with low-salt wash buffer, high-salt wash buffer, LiCl wash buffer,
and Tris-EDTA buffer. The precipitates were eluted with elution buffer (1% SDS, 100 mM
NaHCO3). To reverse the cross-linking, 5 M NaCl and RNase were added, and the samples
were incubated at 65 °C overnight. The extracted DNA was analyzed by polymerase chain
reaction (PCR) using primers spanning the proximal (nt +87 to +106) or distal (nt −340 to
−359) regions of human COX-2.51 After 35 cycles of amplification, the PCR products were
run on a 2% agarose gel and visualized with ethidium bromide staining.
Statistical Analysis
Our previous studies provide detailed descriptions and discussion of the issues involved in
generating the microarray data, data normalization, and statistical analysis and interpretation.
47, 52 Genes that were upregulated or downregulated in response to PBT-1 treatment were
identified and used for pathway analysis. An upregulated gene had to show a 2-fold increase
in the cDNA microarray. These genes were analyzed further by our in-house data-mining tool
based on KEGG and BIOCARTA pathway databases
(http://biochip.nchu.edu.tw/SpecificDB/mouse.html).
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Figure 1. Structure and cytotoxic activity of PBT-series compounds in lung cancer cells
(A) Chemical structures of PBT compounds. (B) CL1-0 cells were treated with various PBT
compounds as indicated for 48 h. The viable cells were detected with an MTS assay. PBT-1,
PBT-2, PBT-9, and PBT-10 exhibited dose-dependent growth inhibition, and the IC50 values
were 0.81, 0.44, 0.37, and 0.46 µg/mL, respectively.
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Figure 2. Growth inhibition and loss of clonogenicity in lung cancer cell lines
(A) Various cells were treated with an increasing concentration of PBT-1 of 0, 0.1, 0.25, 0.5,
and 0.75 µg/mL for 48 h. The viable cells were detected with an MTS assay. (B) The changes
in cell morphology were observed microscopically. The number of viable cells of CL1-5
decreased markedly at a dose of 1 µg/mL of PBT-1. (C) Five hundred cells were plated in soft
agar as illustrated with different concentrations of PBT-1 of 0, 0.05, 0.1, 0.25, and 0.5 µg/mL,
and then incubated for three weeks. The cells were fixed with 4% paraformaldehyde and stained
with 0.01% crystal violet for 16 h. The inhibitory effect of PBT-1 on the colony formation of
CL1-0 cells was determined as the percentage of visible colony numbers in the drug-treated
groups compared with the untreated control groups. The data are expressed as the mean ± SD.
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Figure 3. PBT-1 induces cell cycle arrest in G2-M phase and activates apoptotic proteins
(A) CL1-0 cells/dish (2 × 105) were seeded onto each 60 mm dish and incubated for 24 h.
Various concentrations of PBT-1 were added to the culture medium and incubated for an
additional 2, 6, 12, 16, and 24 h. Cells were then harvested and analyzed by flow cytometry.
The cell cycle phase distribution was determined using CellQuest software. (B) CL1-0 cells
were treated with increasing concentrations of PBT-1 for 24 h or 0.5 µg/mL for the time
indicated. The expression levels of cell cycle regulatory proteins were analyzed by Western
blotting. (C) CL1-0 cells were treated with increasing concentrations of PBT-1 for 24 h, stained
with Fluor 488 Annexin V and PI, and analyzed by flow cytometry. The percentage of apoptotic
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cells is shown in the following table. (D) The expression levels of PARP-1 were analyzed by
Western blotting, with actin expression as the internal control.
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PBT-1 induced genes in different pathways according to the KEGG and BIOCARTA pathway
databases. PBT-1–induced genes are colored red, and the red numbers close to the genes
indicate the fold increase. PBT-1–suppressed genes are colored green. (A) Cell cycle pathway.
(B) Apoptosis pathway. The hypothetical PBT-1–regulated signaling pathways were modified
from the KEGG and BIOCARTA databases.
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Figure 5. PBT-1 inhibition of the NF-κB signaling pathway correlates with suppression of Akt
activity
(A) CL1-0 cells were treated with increasing concentrations of PBT-1 for 24 h. The activity
and expression levels of Akt and IκB were analyzed by Western blotting. (B) CL1-0 cells were
transiently transfected with pNF-κB-Luc vector and pSV-β-galactosidase vector as the internal
control for 20 h. The medium was then changed to serum-free medium without or with
increasing concentrations of PBT-1 as indicated for 1 h, and the cells were stimulated with
various concentration of TNF-α as indicated for 4 h. The luciferase and β-galactosidase
activities were measured using the Luciferase Assay Kit and Galacto-Light Plus™ system.
One representative experiment (n=3, independent transfection/treatment) is shown. All data
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are presented as mean ± SD. (C, D) CL 1-0 and A549 cells were serum starved overnight,
pretreated with various concentrations of PBT-1 as indicated, and then stimulated with TNF-
α as indicated for 4 h. The cell extract was probed with specific antibodies as indicated. A
representative Western blot is shown. (E) Chromatin immunoprecipitation (ChIP) assays were
performed on untreated control A549 cells and on cells treated with PBT-1 and TNF-α as
indicated for 4 h. The extracted chromatin was immunoprecipitated with anti-RelA, anti-p50,
and anti-RelB antibodies as indicated. The recovered DNA was amplified by PCR using
primers covering the region of the COX2 promoter from nt −359 to +106. Control
amplifications were performed on preimmunoprecipitated (“input”) chromatin. A
representative ChIP is shown.
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